AV-380

AVEO Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	AV-380
Sponsor	AVEO Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia (PHASE1)
A Phase 1 Study of AV-380 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AV-380 CI brief — competitive landscape report
AV-380 updates RSS · CI watch RSS
AVEO Pharmaceuticals, Inc. portfolio CI